Jazz to Present Six AAN Abstracts Showcasing EpiCom TSC Reductions and Xywav >9g Gains
Jazz Pharmaceuticals will present six abstracts April 18-22 at AAN on Epidiolex in LGS, Dravet and TSC plus Xywav in narcolepsy. A 6-month EpiCom analysis in TSC showed reductions in behavioral severity, a 7,800-patient claims analysis examined persistence factors, and DUET participants on >9g Xywav reported cognitive and functional gains.
1. Presentation Overview
Jazz Pharmaceuticals will present six abstracts, including one oral presentation, at the American Academy of Neurology Annual Meeting April 18-22 in Chicago. The program spans real-world and clinical data on Epidiolex for Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, alongside Xywav research in narcolepsy.
2. EpiCom TSC and Persistence Data
An oral presentation will detail a prespecified 6-month intermediate analysis of the Phase 3b/4 EpiCom study in TSC patients, showing significant reductions in behavioral severity across TAND-SQ, ABC subscales and CGI-S scales. A separate poster analyzes claims data from over 7,800 patients to identify sociodemographic and clinical factors affecting long-term Epidiolex adherence.
3. DUET Study Xywav Findings
A poster from the DUET study highlights improvements in cognitive complaints, daily functioning, work productivity and disease burden among adults with narcolepsy who optimized Xywav dosage above 9 grams per night. Participants achieving doses up to 12 grams reported greater gains than those on the current 6-9 gram recommendation.